Navigation Links
Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010
Date:10/27/2010

TORONTO, Oct. 27 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European arthroscope market generated over $30 million in 2010. Revenues, however, remained relatively flat over 2009 due to decreasing scope prices and greater market penetration of refurbished scopes.

Due to unfavorable economic conditions, manufacturers are being forced to promote creative options for purchasing arthroscopes to help maintain positive market growth over the next five years. Instead of purchasing a scope up front as a piece of capital equipment, European health care facilities are increasingly purchasing arthroscopes as part of a multi-year endoscope service contract. Leasing and long-term agreements without up-front costs have become more attractive to facilities as capital equipment expenditures decreased following the economic downturn. For endoscope manufacturers, these new purchasing and leasing options will continue to generate revenues by minimizing company losses to third-party endoscope refurbishing companies.

"Endoscope servicing and exchange programs -- such as the KARL STORZ's EndoProtect1 Programs, Stryker's Total Advantage Service and Maintenance Programs, and Smith & Nephew's AGILE-CARE Instrument Services -- are ways for companies to retain customers and gain new customers," says Kai Tuomi, Analyst at MRG. "Service agreements include options such as free loaners, staff training, unlimited repairs, technical support, on-site pickup and delivery, and on-site repairs. Free loaners that can be made available immediately, along with quick turnaround time on repairs, are important factors allowing hospitals to maximize their procedure volumes. By creating these service products for clients, manufacturers are able to reduce the burden health care facilities face when purchasing capital equipment up front, and are able to lock in clients for long-term contracts for both arthroscope purchases and servicing arrangements."

MRG's European Markets for Arthroscopy Devices 2011 report provides critical insight into trends that will fuel and limit market growth for arthroscopy devices in Europe, with coverage of France, Germany, Italy, Spain, and the UK. The report includes a breakdown of unit volumes, average selling prices, and market values for powered shaver disposables, fluid management disposables, radiofrequency probes, arthroscopes, and hand instruments used in arthroscopic procedures to treat injuries within the joints. In addition, the report provides an extensive breakdown of arthroscopic procedures as they relate to the knee, shoulder, ankle, wrist, elbow, and hip joints.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges
2. Despite Potential Risk of Serious Birth Defects, New Study Finds Poor Adherence to Oral Contraception among Women on Category X Medications
3. Despite Dramatic Changes, the Crohns Disease Drug Market Will Experience Only Moderate Growth Through 2019
4. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
5. Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America
6. Medical Affairs Budget & Staffing Remain Top Challenges Despite Increased Funding
7. UBM Japan Pharma Events Grow Despite Air Travel Disruptions
8. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
9. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
10. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
11. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):